Incyte To Present Late-Breaking Phase 3 Results For Retifanlimab And Initial Data From Phase 1 CDK2 Inhibitor Program At The ESMO Congress 2024
Incyte To Present Late-Breaking Phase 3 Results For Retifanlimab And Initial Data From Phase 1 CDK2 Inhibitor Program At The ESMO Congress 2024
- Presidential Symposium to feature Phase 3 retifanlimab (Zynyz) results in squamous cell anal carcinoma (SCAC); filing of supplemental Biologics License Application (sBLA) in SCAC planned by year end 2024
- 總統研討會將展示第 3 期雷替凡利單抗（Zynyz）在鱗狀細胞肛癌（SCAC）中的結果；計劃於 2024 年年底申請補充生物製品許可申請（sBLA）在SCAC中的使用。
- Mini oral presentation to highlight initial Phase 1 data from potential first-in-class CDK2 inhibitor program in patients with CCNE1 ovarian and other advanced cancers
- 迷你口頭報告將重點介紹潛在首例 CDK2 抑制劑項目在患有 CCNE1 卵巢癌和其他晚期癌症患者中的初步 1 期數據。
- Incyte to host an in-person analyst and investor event to review key data at ESMO, including new results from a later CDK2 data cut-off, on Saturday, September 14, 2024, from 1:00-2:30 p.m. ET (7:00-8:30 p.m. CEST)
- 因塞特將舉辦一次面對面的分析師和投資者活動，審查ESMO的關鍵數據，包括來自後續 CDK2 數據截止日的新結果，時間爲 2024 年 9 月 14 日，下午 1:00-2:30 美國東部時間（晚上 7:00-8:30 中歐時間）。
Incyte (NASDAQ:INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2024, to be held September 13-17 in Barcelona and virtually.
因塞特（納斯達克：INCY）今日宣佈，公司將在即將舉行的 2024 年歐洲醫學腫瘤學會（ESMO）大會上，展示其腫瘤學組合中的關鍵數據，大會將於 9 月 13-17 日在巴塞羅那舉行，並提供虛擬會議。